Tao et al.19reported that miR‐152‐3p promotes the Toll‐like receptor (TLR)‐mediated CD4+ T cell inflammatory response by regulating the DNMT1/MyD88 signalling pathway, which may be considered as a new target for SLE treatment. Here, MYD88 is linked to systemic lupus erythematosus.